

Kindred Biosciences, Inc.

Form 3/A

April 28, 2014

FORM 3**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB
Number: 3235-0104Expires: January 31,
2005Estimated average
burden hours per
response... 0.5**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting
Person *

Â GALLIKER STEPHEN S

(Last)

(First)

(Middle)

C/O KINDRED
BIOSCIENCES, INC., Â 1499
BAYSHORE HIGHWAY,
SUITE 226

(Street)

BURLINGAME, Â CA Â 94010

(City)

(State)

(Zip)

2. Date of Event Requiring
Statement

(Month/Day/Year)

12/11/2013

3. Issuer Name and Ticker or Trading Symbol
Kindred Biosciences, Inc. [KIN]4. Relationship of Reporting
Person(s) to Issuer

(Check all applicable)

☐ Director ☐ 10% Owner☒ Officer ☐ Other
(give title below) (specify below)

Chief Financial Officer

5. If Amendment, Date Original
Filed (Month/Day/Year)

12/11/2013

6. Individual or Joint/Group
Filing (Check Applicable Line)
☒ Form filed by One Reporting
Person
☐ Form filed by More than One
Reporting Person**Table I - Non-Derivative Securities Beneficially Owned**1. Title of Security
(Instr. 4)2. Amount of Securities
Beneficially Owned
(Instr. 4)3. Ownership
Form:
Direct (D)
or Indirect
(I)
(Instr. 5)4. Nature of Indirect Beneficial
Ownership
(Instr. 5)

Common Stock

65,773

I

Held by Equity Trust Company,
Custodian FBO Stephen Galliker
IRA ⁽¹⁾Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of
information contained in this form are not
required to respond unless the form displays a
currently valid OMB control number.****Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

Edgar Filing: Kindred Biosciences, Inc. - Form 3/A

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (right to buy)	09/11/2014	09/11/2023	Common Stock	25,000	\$ 1.37	D	Â
Stock Option (right to buy)	Â (2)	11/09/2023	Common Stock	25,000	\$ 3.83	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
GALLIKER STEPHEN S C/O KINDRED BIOSCIENCES, INC. 1499 BAYSHORE HIGHWAY, SUITE 226 BURLINGAME, CA 94010	Â	Â	Â Chief Financial Officer	Â

Signatures

/s/ Stephen S.
Galliker

04/25/2014

__Signature of
Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Held by Equity Trust Company Custodian FBO Stephen Galliker IRA. The Reporting Person has sole voting and disposition power over the shares.
- (2) The option vests as to 25% of the shares on November 9, 2014, with the remaining shares to vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting dates.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.